X0708 D LIVE 0002151604 Epicrispr Biotechnologies, Inc. 7000 SHORELINE COURT, STE 100 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 510-934-7574 DELAWARE None None Corporation true Amber Salzman c/o Epicrispr Biotechnologies, Inc. 7000 SHORELINE COURT, STE 100 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 Executive Officer Director Haorui Zhang c/o Epicrispr Biotechnologies, Inc. 7000 SHORELINE COURT, STE 100 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 Executive Officer Director Lei Qi c/o Epicrispr Biotechnologies, Inc. 7000 SHORELINE COURT, STE 100 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 Director Andrew Lam c/o Epicrispr Biotechnologies, Inc. 7000 SHORELINE COURT, STE 100 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 Director Jennifer King c/o Epicrispr Biotechnologies, Inc. 7000 SHORELINE COURT, STE 100 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 Director Eric Crombez c/o Epicrispr Biotechnologies, Inc. 7000 SHORELINE COURT, STE 100 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 Director Anran Li c/o Epicrispr Biotechnologies, Inc. 7000 SHORELINE COURT, STE 100 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 Director Biotechnology Decline to Disclose 06b false 2018-05-04 true true true true false 0 212755230 176754406 36000824 Series Seed Preferred: $2,499,999.60; Series A-1 Preferred: $51,449,986.60; Series B Preferred: $58,055,021.19; Series B warrants: $1,225.78; Series B-1 Preferred: $10,750,000; Series C Preferred: $53,999,398.66; Series C warrants: $35,999,598.70. false 47 0 0 0 false Epicrispr Biotechnologies, Inc. /s/ Amber Salzman Amber Salzman Chief Executive Officer 2026-08-25